Emerging Potential of Citrus Flavanones as an Antioxidant in Diabetes and its Complications

Current Topics in Medicinal Chemistry

Volumn 15, Issue 2, 2015, Pages 187-195

  Sharma, Malvika ^a   Akhtar, Nadeem ^a   Sambhav, Kumar ^a   Shete, Ganesh ^a   Bansal, Arvind K ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Anti oxidant; Citrus flavanones; Diabetes; Diabetic cardiomyopathy; Diabetic neuropathy; Diabetic retinopathy; Oxidative stress

Indexed keywords

ADIPONECTIN; AGLYCONE; AURANTIIN; CYCLODEXTRIN; FLAVANONE DERIVATIVE; HESPERETIN; HESPERIDIN; INTERLEUKIN 6; NARINGENIN; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTIOXIDANT;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; GENE EXPRESSION; HUMAN; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; TISSUE INJURY; CHEMISTRY; CITRUS; DIABETES COMPLICATIONS; DRUG EFFECTS; METABOLISM;

ANTIOXIDANTS; CITRUS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FLAVANONES; HUMANS; OXIDATIVE STRESS;

EID: 84926308439     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666141209163013     Document Type: Article

References (77)

1. International Diabetes Federation. IDF Diabetes Atlas, International Diabetes Federation (Ed), 6th Edn. Brussels: International Diabetes Federation; 2013.
2. Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. Circ. Res., 2010, 9, 1058-1070.
3. Bolwell, G.P.; Wojtaszek, P. Mechanisms for the generation of reactive oxygen species in plant defence a broad perspective. Physiol. Mol. Plant Pathol., 1997, 6, 347-366.
4. Chen, Q.; Vazquez, E. J.; Moghaddas, S.; Hoppel, C. L.; Lesnefsky, E. J. Production of reactive oxygen species by mitochondria central role of complex III. J. Biol. Chem., 2003, 38, 36027-36031.
5. Rolo, A. P.; Palmeira, C. M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol., 2006, 2, 167-178.
6. Negi, G.; Kumar, A.; Joshi, R.P.; Sharma, S.S. Oxidative Stress and Diabetic Neuropathy: Current Status of Antioxidants. IIOAB J., 2011, 6, 71-78.
7. Pop-Busui, R.; Marinescu, V.; Van Huysen, C.; Li, F.; Sullivan, K.; Greene, D.A.; Larkin, D.; Stevens, M. J. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-Lcarnitine administration. Diabetes, 2002, 8, 2619-2628.
8. Giugliano, D.; Ceriello, A.; Paolisso, G. Oxidative stress and diabetic vascular complications. Diabetes care, 1996, 3, 257-267.
9. Tomlinson, D. R.; Gardiner, N. J. Glucose neurotoxicity. Nat. Rev. Neurosci., 2008, 1, 36-45.
10. de M Bandeira, S.; da Fonseca, L. J.; da S Guedes, G.; Rabelo, L. A.; Goulart, M. O.; Vasconcelos, S. M. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. Int. J. Mol. Sci., 2013, 2, 3265-3284.
11. Bierhaus, A.; Schiekofer, S.; Schwaninger, M.; Andrassy, M.; Humpert, P. M.; Chen, J.; Hong, M.; Luther, T.; Henle, T.; Kloting, I. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes, 2001, 12, 2792-2808.
12. Golbidi, S.; Alireza Ebadi, S.; Laher, I. Antioxidants in the treatment of diabetes. Curr. Diabetes Rev., 2011, 2, 106-125.
13. Nakagami, T.; Nanaumi-Tamura, N.; Toyomura, K.; Nakamura, T.; Shigehisa, T. Dietary flavonoids as potential natural biological response modifiers affecting the autoimmune system. J. Food Sci., 1995, 4, 653-656.
14. Lu, M. F.; Xiao, Z. T.; Zhang, H. Y. Where do health benefits of flavonoids come from? Insights from flavonoid targets and their evolutionary history. Biochem. Biophys. Res. Commun., 2013, 4, 701-704.
15. Kanaze, F.I.; Bounartzi, M.I.; Georgarakis, M.; Niopas, I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur. J. Clin. Nutr., 2007, 61, 472-477.
16. Bilia, A.R.; Isacchi, B.; Righeschi, C.; Guccione, C.; Bergonzi, M.C. Flavonoids Loaded in Nanocarriers: An Opportunity to Increase Oral Bioavailability and Bioefficacy. Food Nutr. Sci., 2014, 5, 1212-1227.
17. Shulman, M.; Cohen, M.; Soto-Gutierrez, A.; Yagi, H.; Wang, H.; Goldwasser, J.; Lee-Parsons, C.W.; Benny-Ratsaby, O.; Yarmush, M.L.; Nahmias, Y. Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. PLoS One, 2011, 6, e18033.
18. Yen, F.L.; Wu, T.H.; Lin, L.T.; Cham, T.M.; Lin, C.C. Naringeninloaded nanoparticles improve the physicochemical properties and the hepatoprotective effects of naringenin in orally-administered rats with CCl(4)-induced acute liver failure. Pharm. Res., 2009, 26, 893-902.
19. Fathi, M.; Varshosaz, J.; Mohebbi, M.; Shahidi F. Hesperetin-Loaded Solid Lipid Nanoparticles and Nanostructure Lipid Carriers for Food Fortification: Preparation, Characterization, and Modeling. Food Bioprocess Tech., 2013, 6, 1464-1475.
20. Rice-Evans, C. A.; Miller, N. J.; Paganga, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med., 1996, 7, 933-956.
21. Mershiba, S. D.; Dassprakash, M. V.; Saraswathy, S. D. Protective effect of naringenin on hepatic and renal dysfunction and oxidative stress in arsenic intoxicated rats. Mol. Biol. Rep., 2013, 5, 3681-3691.
22. Ali, M.M.; El Kader, M.A. A. The influence of naringin on the oxidative state of rats with streptozotocin-induced acute hyperglycaemia. Z. Naturforsch. C., 2004, 59,726-733.
23. Lou, H.; Jing, X.; Wei, X.; Shi, H.; Ren, D.; Zhang, X. Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway. Neuropharmacol., 2014, 79, 380-388.
24. Kaspar, J. W.; Niture, S. K.; Jaiswal, A. K. Nrf2: INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med., 2009, 9, 1304-1309.
25. Jin, Y. R.; Han, X. H.; Zhang, Y. H.; Lee, J. J.; Lim, Y.; Chung, J. H.; Yun, Y. P. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-γ phosphorylation and cyclooxygenase-1 activity. Atherosclerosis, 2007, 1, 144-152.
26. Jayaraman, J.; Jesudoss, V. A.; Menon, V. P.; Namasivayam, N. Anti-inflammatory role of naringenin in rats with ethanol induced liver injury. Toxicol. Mech. Methods, 2012, 7, 568-576.
27. Park, H.Y.; Kim, G.Y.; Choi, Y.H. Naringenin attenuates the release of pro-inflammatory mediators from lipopolysaccharidestimulated BV2 microglia by inactivating nuclear factor-κB and inhibiting mitogen-activated protein kinases. Int. J. Mol. Med., 2012, 1, 204-210.
28. Annadurai, T.; Muralidharan, A.R.; Joseph, T.; Hsu, M.J.; Thomas, P.A.; Geraldine, P. Antihyperglycemic and antioxidant effects of a flavanone, naringenin, in streptozotocin nicotinamide-induced experimental diabetic rats. J. Physiol. Biochem., 2012, 3, 307-318.
29. Jung, U. J.; Lee, M. K.; Jeong, K. S.; Choi, M. S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J. Nutr., 2004, 10, 2499-2503.
30. Ahmed, O.M.; Mahmoud, A.M.; Abdel-Moneim, A.; Ashour, M.B. Antidiabetic effects of hesperidin and naringin in type 2 diabetic rats. Diabetol. Croat., 2012, 2, 53-67.
31. Roy, S.; Rahaman, N.; Ahmed, F.; Metya, S.; Sannigrahi, S. Naringenin attenuates testicular damage, germ cell death and oxidative stress in streptozotocin induced diabetic rats: naringenin prevents diabetic rat testicular damage. J. Appl. Biomed., 2013, 3, 195-208.
32. Rayidi, S. Effect of Naringenin on carbohydrate metabolism in streptozotocin-nicotinamide induced diabetic rats. Biomirror, 2011, 1-9.
33. Goldwasser, J.; Cohen, P. Y.; Yang, E.; Balaguer, P.; Yarmush, M. L.; Nahmias, Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARα, PPARγ and LXRα. PLoS One, 2010, 8, e12399.
34. Rangwala, S.M.; Lazar, M.A. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol. Sci., 2004, 6, 331-336.
35. Amic, D.; Davidovic-Amic, D.; Beslo, D.; Trinajstic, N. Structureradical scavenging activity relationships of flavonoids. Croat. Chem. Acta, 2003, 1, 55-61.
36. Heim, K.E.; Tagliaferro, A.R.; Bobilya, D.J. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J. Nutr. Biochem., 2002, 10, 572-584.
37. Li, W. L.; Zheng, H.C.; Bukuru, J.; De Kimpe, N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J. Ethnopharmacol., 2004, 1, 1-21.
38. Akiyama, S.; Katsumata, S.; Suzuki, K.; Ishimi, Y.; Wu, J.; Uehara, M. Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J. Clin. Biochem Nutr., 2010, 1, 87-92.
39. Kodama, H.; Fujita, M.; Yamaguchi, I. Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia, 1994, 8, 739-744.
40. Lee, G.H.; Proenca, R.; Montez, J.M.; Carroll, K.M.; Darvishzadeh, J.G.; Lee, J.I.; Friedman, J. M. Abnormal splicing of the leptin receptor in diabetic mice. Nature, 1996, 632-635.
41. Mahmoud, A.M.; Ashour, M.B.; Abdel-Moneim, A.; Ahmed, O. M. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J. Diabetes Complications, 2012, 6, 483-490.
42. Kola, B.; Boscaro, M.; Rutter, G.A.; Grossman, A.B.; Korbonits, M. r. Expanding role of AMPK in endocrinology. Trends Endocrinol. Metab., 2006, 5, 205-215.
43. Zhang, K.; Kaufman, R.J. From endoplasmic-reticulum stress to the inflammatory response. Nature, 2008, 454, 455-462.
44. Malhotra, J.D.; Kaufman, R.J. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid. Redox Signal., 2007, 9, 2277-2293.
45. Eizirik, D.L.; Cardozo, A.K.; Cnop, M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev., 2008, 29, 42-61.
46. Oshitari, T.; Hata, N.; Yamamoto, S. Endoplasmic reticulum stress and diabetic retinopathy. Vasc. Health. Risk. Manag., 2008, 4, 115-22.
47. Sharma, A.K.; Bharti, S.; Ojha, S.; Bhatia, J.; Kumar, N.; Ray, R.; Kumari, S; Arya, D.S. Up-regulation of PPARγ, heat shock protein-27 and-72 by naringin attenuates insulin resistance, β-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. Br. J. Nutr., 2011, 106, 1713-1723.
48. Kumar, A.; Prakash, A.; Dogra, S. Naringin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress induced by D-galactose in mice. Food Chem. Toxicol., 2010, 48, 626-632.
49. Mahmoud, A.M.; Ashour, M.B.; Abdel-Moneim, A.; Ahmed, O.M. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J. Diabetes Complications., 2012, 26, 483-490.
50. Zychowska, M.; Rojewska, E.; Przewlocka, B.; Mika, J. Mechanisms and pharmacology of diabetic neuropathy-experimental and clinical studies. Pharm. Rep., 2013, 6, 1601-1610.
51. Joshi, R. P.; Negi, G.; Kumar, A.; Pawar, Y. B.; Munjal, B.; Bansal, A. K.; Sharma, S. S. SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: An insight into its mechanism for neuroprotection. Nanomedicine, 2013, 6, 776-785.
52. Vincent, A. M.; Russell, J. W.; Low, P.; Feldman, E. L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev., 2004, 4, 612-628.
53. Cameron, N.E.; Cotter, M.A. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr. Drug Targets, 2008, 1, 60-67.
54. Kandhare, A.D.; Raygude, K.S.; Ghosh, P.; Ghule, A.E.; Bodhankar, S. L. Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia, 2012, 4, 650-659.
55. Kaulaskar, S.; Bhutada, P.; Rahigude, A.; Jain, D.; Harle, U. Effects of naringenin on allodynia and hyperalgesia in rats with chronic constriction injury-induced neuropathic pain. J. Chinese Integrative Med., 2012, 10(12) 1482-1489.
56. Visnagri, A.; Kandhare, A.D.; Chakravarty, S.; Ghosh, P.; Bodhankar, S. L. Hesperidin, a flavanoglycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions. Pharm. Biol., 2014, 52 (7), 814-28.
57. Kumar, A.; Kaundal, R. K.; Iyer, S.; Sharma, S. S. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci., 2007, 13, 1236-1244.
58. Negi, G.; Kumar, A.; Sharma, S. S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J. Pineal. Res., 2011, 2, 124-131.
59. Saini, A.K.; Kumar Hs, A.; Sharma, S.S. Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. Eur. J. Pharmacol., 2007, 1, 164-172.
60. Kumar, A.; Negi, G.; Sharma, S.S. JSH-23 targets nuclear factorkappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes. Metab., 2011, 8, 750-758.
61. Sharma, S.S.; Sayyed, S.G. Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy. Clin. Exp. Pharmacol. Physiol., 2006, 11, 1022-1028.
62. Boudina, S.; Abel, E.D. Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord., 2010, 1, 31-39.
63. Bugger, H.; Abel, E. D. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia, 2014, 660-671.
64. Xu, Y. J.; Tappia, P. S.; Neki, N. S.; Dhalla, N. S. Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. Heart Fail. Rev., 2013, 1, 113-121.
65. Asbun, J.; Villarreal, F. J. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J. Am. Coll. Cardiol., 2006, 4, 693-700.
66. Owira, P.M.; Ojewole, J.A. The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives: review article. Cardiovasc. J. Afr., 2010, 5, 280-285.
67. Yang, Y.; Wolfram, J.; Shen, H.; Fang, X.; Ferrari, M. Hesperetin: An inhibitor of the transforming growth factor-β (TGF-β) signaling pathway. Eur. J. Med. Chem., 2012, 58, 390-395.
68. Orallo, F.; Alvarez, E.; Basaran, H.; Lugnier, C. Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn-Schmiedeberg's Arch. Pharmacol., 2004, 6, 452-463.
69. Rajadurai, M.; Stanely Mainzen Prince, P. Preventive effect of naringin on isoproterenol-induced cardiotoxicity in Wistar rats: an in vivo and in vitro study. Toxicology, 2007, 3, 216-225.
70. Huang, H.; Wu, K.; You, Q.; Huang, R.; Li, S. Naringin inhibits high glucose-induced cardiomyocyte apoptosis by attenuating mitochondrial dysfunction and modulating the activation of the p38 signaling pathway. Int. J. Mol. Med., 2013, 2, 396-402.
71. Ding, J.; Wong, T. Y. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr. Diab. Rep., 2012, 4, 346-354.
72. Kowluru, R.A.; Chan, P.S. Oxidative stress and diabetic retinopathy. Exp. Diabetes Res., 2007, 1-12. doi: 10.1155/2007/43603
73. Kumar, B.; Gupta, S.K.; Srinivasan, B.P.; Nag, T.C.; Srivastava, S.; Saxena, R.; Jha, K. A. Hesperetin rescues retinal oxidative stress, neuroinflammation and apoptosis in diabetic rats. Microvasc. Res., 2013, 87, 65-74.
74. Kumar, B.; Gupta, S.K.; Srinivasan, B. P.; Nag, T.C.; Srivastava, S.; Saxena, R. Hesperetin ameliorates hyperglycemia induced retinal vasculopathy via anti-angiogenic effects in experimental diabetic rats. Vasc. Pharmacol., 2012, 5, 201-207.
75. Shi, X.; Liao, S.; Mi, H.; Guo, C.; Qi, D.; Li, F.; Zhang, C.; Yang, Z. Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Molecules, 2012, 11, 12868-12881.
76. Huang, H.; Gandhi, J. K.; Zhong, X.; Wei, Y.; Gong, J.; Duh, E. J.; Vinores, S. A. TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest. Ophthalmol. Vis. Sci., 2011, 3, 1336-1344.
77. Akiyama, S.; Katsumata, S.; Suzuki, K.; Nakaya, Y.; Ishimi, Y.; Uehara, M. Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes. Biosci. Biotechnol. Biochem., 2009, 12, 2779-2782.